Amendment 20: DRIVe EZ Broad Agency Announcement

EZBAA-22-100-SOL-00003

Amendment #020

Office of Biomedical Advanced Research and Development Authority Division of Research, Innovation & Ventures (DRIVe)
Easy Broad Agency Announcement EZBAA-22-100-SOL-00003

The purpose of Amendment #020 is the following:

1) Pause the following Area of Interest (AOI):
AOI #26: Agnostic Diagnostic
2) Add a topic to the following Area of Interest (AOI): AOI #20: DRIVe Forward
3) Update the closing date for the following Area of
Interest (AOI):
AOI #20: DRIVe Forward

EZBAA-22-100-SOL-00003

Amendment #020

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Pausing the following research Area of Interest (AOI):
AOI #26: Agnostic Diagnostic

2)

Adding a topic for the following research Area of Interest (AOI): AOI #20: DRIVe Forward
We are seeking abstract submissions for the following AOI:

AOI #20 DRIVe Forward
The continual threat of known and unknown emerging infectious diseases, pandemics, and other public health emergencies requires us to continually invest in products, capabilities, and technologies that have the potential to radically reshape and strengthen our ability to prevent, prepare for, and respond to those emergencies. Specifically, the Division of Research, Innovation, and Ventures (DRIVe) aims to develop products, capabilities, and technologies to rapidly and agnostically detect threats, improve patient care, including ancillary supplies and resources, as well as novel approaches to develop, clinically validate, and deploy/distribute medical countermeasures (MCMs). DRIVe and BARDA already ha ve a variety of specific programs, each focused on specific problems or threat areas of interest, that address this broader aim. DRIVe recognizes, however, that many promising approaches don’t fit into any current program areas but would nonetheless advance DRIVe’s mission. Accordingly, submissions under this DRIVe Forward Area of Interest are designed to capture those blindspots either as a standalone proof of concepts or as a prelude to a potential future program. DRIVe Forward aims to support proposals t hat are not only outside the scope of other programs but also address high risk, high reward innovation which will promote the mission of BARDA to defend the nation against biomedical threats. We are interested in proposals that aim to address the following four topics. Note, these topics will be updated regularly.
•

Topic #1: Enhancing vaccine efficacy: Vaccine efficacy can greatly vary amongst individuals and